GOVX GeoVax Labs Inc
Price (delayed)
$1.18
Market cap
$16.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.82
Enterprise value
$10.82M
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On
Highlights
The EPS has soared by 66% year-on-year and by 48% since the previous quarter
The quick ratio has contracted by 43% from the previous quarter but it has grown by 8% YoY
GeoVax Labs's net income has increased by 3.8% YoY but it has decreased by 2.8% from the previous quarter
The equity has declined by 41% since the previous quarter and by 12% year-on-year
Key stats
What are the main financial stats of GOVX
Market
Valuations
Earnings
Shares outstanding
13.84M
Market cap
$16.33M
Enterprise value
$10.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$29.1M
Net income
-$24.99M
EBIT
-$24.97M
EBITDA
-$24.88M
Free cash flow
-$24.7M
Per share
Balance sheet
Liquidity
EPS
-$4.82
EPS diluted
-$4.82
Free cash flow per share
-$4.76
Book value per share
$0.54
Revenue per share
$0
TBVPS
$1.57
Total assets
$8.16M
Total liabilities
$3.11M
Debt
$0
Equity
$5.05M
Working capital
$4.83M
Debt to equity
0
Current ratio
2.55
Quick ratio
1.98
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-374.1%
Return on equity
-884.9%
Return on invested capital
N/A
Return on capital employed
-494.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GOVX stock price
How has the GeoVax Labs stock price performed over time
Intraday
9.26%
1 week
-13.87%
1 month
-18.06%
1 year
-38.54%
YTD
-52.23%
QTD
11.32%
Financial performance
How have GeoVax Labs's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.1M
Net income
-$24.99M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 9% YoY and by 5% from the previous quarter
GeoVax Labs's net income has increased by 3.8% YoY but it has decreased by 2.8% from the previous quarter
Growth
What is GeoVax Labs's growth rate over time
Valuation
What is GeoVax Labs stock price valuation
P/E
N/A
P/B
2.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 66% year-on-year and by 48% since the previous quarter
The P/B is 68% less than the 5-year quarterly average of 6.3
The equity has declined by 41% since the previous quarter and by 12% year-on-year
Efficiency
How efficient is GeoVax Labs business performance
The ROA has dropped by 167% year-on-year and by 7% since the previous quarter
The return on equity has declined by 9% since the previous quarter
Dividends
What is GOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GOVX.
Financial health
How did GeoVax Labs financials performed over time
GOVX's total assets is 162% more than its total liabilities
The quick ratio has contracted by 43% from the previous quarter but it has grown by 8% YoY
The current ratio is down by 39% since the previous quarter but it is up by 14% year-on-year
The debt is 100% smaller than the equity
The equity has declined by 41% since the previous quarter and by 12% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.